Related Experiment Videos
Early and late angiographic and clinical outcome following helistent stent implantation
Ahmet Camsari1, Oben Döven, Hasan Pekdemir
1Department of Cardiology, Faculty of Medicine, Mersin University, Turkey.
Insights
The Helistent stent shows a high success rate in patients with coronary artery disease. It demonstrates promising midterm angiographic and long-term clinical outcomes, with low rates of restenosis and major adverse cardiac events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background:
- Limited data exists on how different stent designs affect restenosis and major adverse cardiac events (MACE) with new antithrombotic therapies.
- Evaluating novel stent designs is crucial for improving long-term patient outcomes in coronary artery disease treatment.
Purpose of the Study:
- To assess the midterm (6 months) and late-term (2 years) clinical and angiographic outcomes of Helistent stent implantation.
- To evaluate the safety and efficacy of the Helistent stent in high-risk patients undergoing coronary interventions with new antiplatelet regimens.
Main Methods:
- A prospective study involving 150 high-risk patients with coronary artery disease who received Helistent stent implantation.
- Coronary angiography was performed at 6 months, with clinical follow-up extending to 2 years.
- Analysis of success rates, angiographic restenosis, target lesion revascularization, and MACE.
Main Results:
- Helistent stent implantation achieved a high success rate of 99%.
- The angiographic restenosis rate was 11.3% at 6 months.
- At 2 years, 16% of patients underwent target lesion revascularization, 20% experienced MACE, and 3.3% died.
Conclusions:
- Helistent stent implantation is a safe and effective procedure with a high success rate.
- The stent demonstrates encouraging midterm angiographic and late clinical outcomes, suggesting its potential in managing coronary artery disease.
- Further research is warranted to compare Helistent with other stent designs in various patient populations.
Abstract:
There is still a lack of data on the influence of different stent designs on long-term restenosis rates and major adverse cardiac events (MACE) with the use of new antithrombotic regimens. We evaluated the midterm (6 months) clinical and angiographic and lateterm (2 years) clinical outcome of Helistent stent implantation. The study population consisted of 150 patients with high risk factor rates who had single or multivessel disease and had undergone coronary Helistent stent implantation with new antiplatelet regimens. The control coronary angiographies were done at 6 months and they were followed clinically to the end of 2 years. In 150 patients, 236 Helistent stents were implanted for 224 lesions. Helistent stent implantation was associated with a very high success rate (99%). The angiographic re-stenosis rate was 11.3% at 6 months. Only 16% of the patients experienced target lesion revascularization, 20% of the patients experienced MACE and of them, only 3.3% died at the end of two year follow-up period. The results demonstrate that the Helistent stent can be implanted with a high success rate with encouraging 6 month angiographic and late clinical outcomes.